[ TRANSACTION RECORD ]

GlaxoSmithKline Investment in Bellus Health — 2023

VERIFIED VECTOR ID: 001911 · tx-107-2
M SOURCE NODE — FUNDER
GlaxoSmithKline
Healthcare United Kingdom
$2,000,000,000
EQUITY
28/06/2023
Q DESTINATION NODE — RECIPIENT
Bellus Health
Company Canada
Amount (USD)
$2.0B
Flow Type
EQUITY
Transaction Date
28/06/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity GlaxoSmithKline
AUM 100000
HQ Location United Kingdom
Sector Healthcare
Recipient Profile [ Q ]
Entity Bellus Health
Entity Type Company
Jurisdiction Canada
Intelligence Note

GlaxoSmithKline (GSK) completed the acquisition of Bellus Health for 2 billion dollars to add a potential first-in-class treatment for chronic cough to its pipeline. The transaction centers on camlipixant, a late-stage therapy for refractory chronic cough. This deal is a significant example of institutional healthcare capital targeting specialty medicines with high commercial potential.

Σ
Primary Forensic Source https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-bellus-health/
✓ SOURCE LINKED